These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 29282636)

  • 21. [New trends of acid-related diseases treatment].
    Koike T; Nakagawa K; Kanno T; Iijima K; Shimosegawa T
    Nihon Rinsho; 2015 Jul; 73(7):1136-46. PubMed ID: 26165070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.
    Okuyama M; Nakahara K; Iwakura N; Hasegawa T; Oyama M; Inoue A; Ishizu H; Satoh H; Fujiwara Y
    Digestion; 2017; 95(4):281-287. PubMed ID: 28501868
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease.
    Miwa H; Igarashi A; Teng L; Uda A; Deguchi H; Tango T
    J Gastroenterol; 2019 Aug; 54(8):718-729. PubMed ID: 30919071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: A systematic review and meta-analysis.
    Simadibrata DM; Syam AF; Lee YY
    J Gastroenterol Hepatol; 2022 Dec; 37(12):2217-2228. PubMed ID: 36181401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin.
    Ono S; Kato M; Nakagawa S; Mabe K; Sakamoto N
    Helicobacter; 2017 Jun; 22(3):. PubMed ID: 28098408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Vonoprazan: a novel potassium-competitive acid blocker].
    Sugano K
    Nihon Rinsho; 2015 Jul; 73(7):1163-8. PubMed ID: 26165074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?
    Dong SQ; Singh TP; Wei X; Yao H; Wang HL
    Helicobacter; 2017 Dec; 22(6):. PubMed ID: 28884937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of Vonoprazan-Based versus Proton Pump Inhibitor-Based Triple Therapy for
    Lyu QJ; Pu QH; Zhong XF; Zhang J
    Biomed Res Int; 2019; 2019():9781212. PubMed ID: 31211144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori.
    Tsujimae M; Yamashita H; Hashimura H; Kano C; Shimoyama K; Kanamori A; Matsumoto K; Koizumi A; Momose K; Eguchi T; Fukuchi T; Fujita M; Okada A
    Digestion; 2016; 94(4):240-246. PubMed ID: 28030862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438).
    Otake K; Sakurai Y; Nishida H; Fukui H; Tagawa Y; Yamasaki H; Karashima M; Otsuka K; Inatomi N
    Adv Ther; 2016 Jul; 33(7):1140-57. PubMed ID: 27287852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High Body Mass Index Is Correlated with the Success of Vonoprazan-Based Second-Line Therapy for Helicobacter Pylori Infection.
    Kasai T; Suzuki S; Kusano C; Ikehara H; Ichijima R; Ohyauchi M; Kawamura M; Yoda Y; Nakahara M; Kawabe K; Gotoda T
    Tohoku J Exp Med; 2021 Feb; 253(2):85-94. PubMed ID: 33536385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux.
    Akiyama J; Hosaka H; Kuribayashi S; Moriyasu S; Hisada Y; Okubo H; Watanabe K; Imbe K; Nagata N; Kojima Y; Yokoi C; Uemura N; Shimoyama Y; Kawamura O; Yamada M; Kusano M
    Digestion; 2020; 101(2):174-183. PubMed ID: 30897577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A systematic review and meta-analysis of the efficacy of vonoprazan for proton pump inhibitor-resistant gastroesophageal reflux disease.
    Simadibrata DM; Lesmana E; Fass R
    J Gastroenterol Hepatol; 2024 May; 39(5):796-805. PubMed ID: 38263507
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.
    Cheng Y; Liu J; Tan X; Dai Y; Xie C; Li X; Lu Q; Kou F; Jiang H; Li J
    Dig Dis Sci; 2021 Jan; 66(1):19-28. PubMed ID: 32095968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication.
    Kajihara Y; Shimoyama T; Mizuki I
    Scand J Gastroenterol; 2017 Feb; 52(2):238-241. PubMed ID: 27806639
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line
    Maruyama M; Tanaka N; Kubota D; Miyajima M; Kimura T; Tokutake K; Imai R; Fujisawa T; Mori H; Matsuda Y; Wada S; Horiuchi A; Kiyosawa K
    Can J Gastroenterol Hepatol; 2017; 2017():4385161. PubMed ID: 28349044
    [No Abstract]   [Full Text] [Related]  

  • 37. Vonoprazan treatment improves gastrointestinal symptoms in patients with gastroesophageal reflux disease.
    Shinozaki S; Osawa H; Hayashi Y; Sakamoto H; Miura Y; Lefor AK; Yamamoto H
    Kaohsiung J Med Sci; 2017 Dec; 33(12):616-622. PubMed ID: 29132551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vonoprazan vs proton pump inhibitors in treating post-endoscopic submucosal dissection ulcers and preventing bleeding: A meta-analysis of randomized controlled trials and observational studies.
    Martin ; Zhou Y; Meng CX; Takagi T; Tian YS
    Medicine (Baltimore); 2020 Feb; 99(9):e19357. PubMed ID: 32118778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of Vonoprazan for Gastroesophageal Reflux Symptoms in Patients with Proton Pump Inhibitor-resistant Non-erosive Reflux Disease.
    Niikura R; Yamada A; Hirata Y; Hayakawa Y; Takahashi A; Shinozaki T; Takeuchi Y; Fujishiro M; Koike K
    Intern Med; 2018 Sep; 57(17):2443-2450. PubMed ID: 29607951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Vonoprazan Triple-Drug Blister Packs on H. pylori Eradication Rates in Japan: Interrupted Time Series Analysis.
    Deguchi H; Yamazaki H; Kamitani T; Yamamoto Y; Fukuhara S
    Adv Ther; 2021 Jul; 38(7):3937-3947. PubMed ID: 34091865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.